RT Journal Article
SR Electronic
T1 To what extent do we need to rely on non-pharmaceutical interventions while COVID-19 vaccines roll out in 2021?
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.02.03.21251108
DO 10.1101/2021.02.03.21251108
A1 Yang, Juan
A1 Marziano, Valentina
A1 Deng, Xiaowei
A1 Guzzetta, Giorgio
A1 Zhang, Juanjuan
A1 Trentini, Filippo
A1 Cai, Jun
A1 Poletti, Piero
A1 Zheng, Wen
A1 Wang, Wei
A1 Wu, Qianhui
A1 Zhao, Zeyao
A1 Dong, Kaige
A1 Zhong, Guangjie
A1 Viboud, Cécile
A1 Merler, Stefano
A1 Ajelli, Marco
A1 Yu, Hongjie
YR 2021
UL http://medrxiv.org/content/early/2021/05/14/2021.02.03.21251108.abstract
AB COVID-19 vaccination is being conducted in over 190 countries/regions to control SARS-CoV-2 transmission and return to a pre-pandemic lifestyle. However, understanding when non-pharmaceutical interventions (NPIs) can be lifted as immunity builds up remain a key question for policy makers. To address it, we built a data-driven model of SARS-CoV-2 transmission for China. We estimated that to prevent the escalation of local outbreaks to widespread epidemics, stringent NPIs need to remain in place at least one year after the start of vaccination. Should NPIs alone be capable to keep the reproduction number (Rt) around 1.3, the synergetic effect of NPIs and vaccination could reduce up to 99% of COVID-19 burden and bring Rt below the epidemic threshold in about 9 months. Maintaining strict NPIs throughout 2021 is of paramount importance to reduce COVID-19 burden while vaccines are distributed to the population, especially in large populations with little natural immunity.Competing Interest StatementH.Y. has received research funding from Sanofi Pasteur, GlaxoSmithKline, Yichang HEC Changjiang Pharmaceutical Company, and Shanghai Roche Pharmaceutical Company. M.A. has received research funding from Seqirus. None of those research funding is related to COVID-19. All other authors report no competing interests.Clinical TrialNo trial ID cause this is a modelling studyFunding StatementThe study was supported by grants from the National Science Fund for Distinguished Young Scholars (No. 81525023), Key Emergency Project of Shanghai Science and Technology Committee (No 20411950100), National Science Fund for Distinguished Young Scholars (No. 81903373), European Union Grant 874850 MOOD (MOOD 000).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All these data were in the public domain. Ethical review for the re-use of these secondary data is not required.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesShould the manuscript be accepted, all data and codes will be provided on GitHub.